Lactate contribution to the tumor microenvironment: Mechanisms, effects on immune cells and therapeutic relevance

Frontiers in Immunology

Volumn 7, Issue FEB, 2016, Pages

  Romero Garcia, Susana ^a   Moreno Altamirano, María Maximina B ^b   Prado Garcia, Heriberto ^a   Sánchez García, Francisco Javier ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Immune escape; L lactate metabolism; Monocarboxylate transporter; Tumor microenvironment; Warburg effect

Indexed keywords

INTERLEUKIN 17; LACTATE DEHYDROGENASE;

CANCER INFILTRATION; CELL SURVIVAL; CELL TRANSFER; DOWN REGULATION; ENZYME ANALYSIS; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MALIGNANT TRANSFORMATION; NONHUMAN; REVIEW; SYMBIOSIS; TUMOR MICROENVIRONMENT; WALKER WARBURG SYNDROME;

EID: 84962526021     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00052     Document Type: Review

References (122)

1. Robergs RA, Ghiasvand F, Parker D. Biochemistry of exercise-induced metabolic acidosis. Am J Physiol Regul Integr Comp Physiol (2004) 287:R502-16. doi: 10.1152/ajpregu.00114.2004.
2. Adeva-Andany M, Lopez-Ojen M, Funcasta-Calderon R, Ameneiros-Rodriguez E, Donapetry-Garcia C, Vila-Altesor M, et al. Comprehensive review on lactate metabolism in human health. Mitochondrion (2014) 17:76-100. doi:10.1016/j.mito.2014.05.007.
3. Consoli A, Nurjhan N, Reilly JJ Jr, Bier DM, Gerich JE. Contribution of liver and skeletal muscle to alanine and lactate metabolism in humans. Am J Physiol (1990) 259:E677-84.
4. van Hall G. Lactate kinetics in human tissues at rest and during exercise. Acta Physiol (Oxf) (2010) 199:499-508. doi:10.1111/j.1748-1716.2010.02122.x.
5. Waterhouse C, Keilson J. Cori cycle activity in man. J Clin Invest (1969) 48:2359-66. doi:10.1172/jci106202.
6. Phypers B, Pierce JT. Lactate physiology in health and disease. Contin Educ Anaesth Crit Care Pain (2006) 6:128-32. doi:10.1093/bjaceaccp/mkl018.
7. Schurr A, Gozal E. Glycolysis at 75: is it time to tweak the first elucidated metabolic pathway in history? Front Neurosci (2015) 9:170. doi:10.3389/fnins.2015.00170.
8. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol (1927) 8:519-30. doi:10.1085/jgp.8.6.519.
9. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 104:19345-50. doi:10.1073/pnas.0709747104.
10. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol (2009) 92:329-33. doi:10.1016/j.radonc.2009.06.025.
11. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 94:6658-63. doi:10.1073/pnas.94.13.6658.
12. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res (2009) 69:7986-93. doi:10.1158/0008-5472.can-09-2266.
13. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 38:487-99. doi:10.1016/j.molcel.2010.05.007.
14. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest (2013) 123:3678-84. doi:10.1172/jci69600.
15. Kuhn KS, Schuhmann K, Stehle P, Darmaun D, Furst P. Determination of glutamine in muscle protein facilitates accurate assessment of proteolysis and de novo synthesis-derived endogenous glutamine production. Am J Clin Nutr (1999) 70:484-9.
16. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene (2010) 29:313-24. doi:10.1038/onc.2009.358.
17. Guerin PJ, Furtak T, Eng K, Gauthier ER. Oxidative stress is not required for the induction of apoptosis upon glutamine starvation of Sp2/0-Ag14 hybridoma cells. Eur J Cell Biol (2006) 85:355-65. doi:10.1016/j.ejcb.2005.11.004.
18. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res (2015) 25:771-84. doi:10.1038/cr.2015.68.
19. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324:1029-33. doi:10.1126/science.1160809.
20. Holm E, Hagmuller E, Staedt U, Schlickeiser G, Gunther HJ, Leweling H, et al. Substrate balances across colonic carcinomas in humans. Cancer Res (1995) 55:1373-8.
21. Mantovani A. Macrophages, neutrophils, and cancer: a double edged sword. New J Sci (2014) 2014:14. doi:10.1155/2014/271940.
22. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol (2015) 194:2985-91. doi:10.4049/jimmunol.1403134.
23. Newsholme P, Gordon S, Newsholme EA. Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages. Biochem J (1987) 242:631-6. doi:10.1042/bj2420631.
24. Galvan-Pena S, O'Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol (2014) 5:420. doi:10.3389/fimmu.2014.00420.
25. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 18:349-55. doi:10.1016/j.semcancer.2008.03.004.
26. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 513:559-63. doi:10.1038/nature13490.
27. Pearce EJ, Everts B. Dendritic cell metabolism. Nat Rev Immunol (2015) 15:18-29. doi:10.1038/nri3771.
28. Zaccagnino P, Saltarella M, Maiorano S, Gaballo A, Santoro G, Nico B, et al. An active mitochondrial biogenesis occurs during dendritic cell differentiation. Int J Biochem Cell Biol (2012) 44:1962-9. doi:10.1016/j.biocel.2012.07.024.
29. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood (2010) 115:4742-9. doi:10.1182/blood-2009-10-249540.
30. Jantsch J, Chakravortty D, Turza N, Prechtel AT, Buchholz B, Gerlach RG, et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol (2008) 180:4697-705. doi:10.4049/jimmunol.180.7.4697.
31. Everts B, Amiel E, Huang SC, Smith AM, Chang CH, Lam WY, et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation. Nat Immunol (2014) 15:323-32. doi:10.1038/ni.2833.
32. Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood (2012) 120:1422-31. doi:10.1182/blood-2012-03-419747.
33. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 16:769-77. doi:10.1016/S1074-7613(02)00323-0.
34. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol (2008) 180:4476-86. doi:10.4049/jimmunol.180.7.4476.
35. Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol (2014) 192:3626-36. doi:10.4049/jimmunol.1302062.
36. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity (2011) 35:871-82. doi:10.1016/j.immuni.2011.09.021.
37. Wang R, Green DR. Metabolic reprogramming and metabolic dependency in T cells. Immunol Rev (2012) 249:14-26. doi:10.1111/j.1600-065X.2012.01155.x.
38. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol (2010) 185:4977-82. doi:10.4049/jimmunol.1001323.
39. Linnebacher M, Maletzki C. Tumor-infiltrating B cells: the ignored players in tumor immunology. Oncoimmunology (2012) 1:1186-8. doi:10.4161/onci.20641.
40. Halestrap AP, Denton RM. Specific inhibition of pyruvate transport in rat liver mitochondria and human erythrocytes by alpha-cyano-4-hydroxycinnamate. Biochem J (1974) 138:313-6. doi:10.1042/bj1380313.
41. Palmieri F, Bisaccia F, Capobianco L, Dolce V, Fiermonte G, Iacobazzi V, et al. Mitochondrial metabolite transporters. Biochim Biophys Acta (1996) 1275:127-32. doi:10.1016/0005-2728(96)00062-X.
42. Price NT, Jackson VN, Halestrap AP. Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past. Biochem J (1998) 329(Pt 2):321-8. doi:10.1042/bj3290321.
43. Cheeti S, Warrier BK, Lee CH. The role of monocarboxylate transporters in uptake of lactic acid in HeLa cells. Int J Pharm (2006) 325:48-54. doi:10.1016/j.ijpharm.2006.06.018.
44. Carpenter L, Halestrap AP. The kinetics, substrate and inhibitor specificity of the lactate transporter of Ehrlich-Lettre tumour cells studied with the intracellular pH indicator BCECF. Biochem J (1994) 304(Pt 3):751-60. doi:10.1042/bj3040751.
45. Simchowitz L, Textor JA. Lactic acid secretion by human neutrophils. Evidence for an H+ + lactate-cotransport system. J Gen Physiol (1992) 100:341-67. doi:10.1085/jgp.100.2.341.
46. Halestrap AP. The monocarboxylate transporter family-structure and functional characterization. IUBMB Life (2012) 64:1-9. doi:10.1002/iub.573.
47. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J (2000) 350(Pt 1):219-27. doi:10.1042/0264-6021:3500219.
48. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest (2013) 123:3685-92. doi:10.1172/jci69741.
49. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature (2012) 487:443-8. doi:10.1038/nature11314.
50. Brooks GA. Lactate: link between glycolytic and oxidative metabolism. Sports Med (2007) 37:341-3. doi:10.2165/00007256-200737040-00017.
51. Gladden LB. A lactatic perspective on metabolism. Med Sci Sports Exerc (2008) 40:477-85. doi:10.1249/MSS.0b013e31815fa580.
52. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 118:3930-42. doi:10.1172/jci36843.
53. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol (2006) 70:2108-15. doi:10.1124/mol.106.026245.
54. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch (2008) 452:139-46. doi:10.1007/s00428-007-0558-5.
55. de Oliveira AT, Pinheiro C, Longatto-Filho A, Brito MJ, Martinho O, Matos D, et al. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr (2012) 44:171-8. doi:10.1007/s10863-012-9408-5.
56. Curry JM, Tuluc M, Whitaker-Menezes D, Ames JA, Anantharaman A, Butera A, et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle (2013) 12:1371-84. doi:10.4161/cc.24092.
57. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP, Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget (2014) 5:11029-37. doi:10.18632/oncotarget.2789.
58. Lim KS, Lim KJ, Price AC, Orr BA, Eberhart CG, Bar EE. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. Oncogene (2014) 33:4433-41. doi:10.1038/onc.2013.390.
59. Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P, et al. Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab (2014) 19:795-809. doi:10.1016/j.cmet.2014.03.003.
60. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 109:3812-9. doi:10.1182/blood-2006-07-035972.
61. Mendler AN, Hu B, Prinz PU, Kreutz M, Gottfried E, Noessner E. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer (2012) 131:633-40. doi:10.1002/ijc.26410.
62. Husain Z, Seth P, Sukhatme VP. Tumor-derived lactate and myeloid-derived suppressor cells: linking metabolism to cancer immunology. Oncoimmunology (2013) 2:e26383. doi:10.4161/onci.26383.
63. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 72:2746-56. doi:10.1158/0008-5472.can-11-1272.
64. Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol (2013) 230:350-5. doi:10.1002/path.4218.
65. Nagae M, Hiraga T, Yoneda T. Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab (2007) 25:99-104. doi:10.1007/s00774-006-0734-8.
66. Kato Y, Ozawa S, Tsukuda M, Kubota E, Miyazaki K, St-Pierre Y, et al. Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma. FEBS J (2007) 274:3171-83. doi:10.1111/j.1742-4658.2007.05848.x.
67. Kato Y, Nakayama Y, Umeda M, Miyazaki K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem (1992) 267:11424-30.
68. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res (2001) 61:6020-4.
69. Xu L, Fukumura D, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem (2002) 277:11368-74. doi:10.1074/jbc.M108347200.
70. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res (1999) 5:3711-21.
71. Shi Q, Le X, Wang B, Xiong Q, Abbruzzese JL, Xie K. Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. J Interferon Cytokine Res (2000) 20:1023-8. doi:10.1089/10799900050198471.
72. Xu L, Fidler IJ. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res (2000) 60:4610-6.
73. Hunt TK, Aslam RS, Beckert S, Wagner S, Ghani QP, Hussain MZ, et al. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal (2007) 9:1115-24. doi:10.1089/ars.2007.1674.
74. Porporato PE, Payen VL, De Saedeleer CJ, Preat V, Thissen JP, Feron O, et al. Lactate stimulates angiogenesis and accelerates the healing of superficial and ischemic wounds in mice. Angiogenesis (2012) 15:581-92. doi:10.1007/s10456-012-9282-0.
75. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res (2011) 71:2550-60. doi:10.1158/0008-5472.can-10-2828.
76. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 8:3984-4001. doi:10.4161/cc.8.23.10238.
77. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal (2012) 16:1264-84. doi:10.1089/ars.2011.4243.
78. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol (1984) 2:343-66. doi:10.1016/S0167-8140(84)80077-8.
79. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Salem AF, Tsirigos A, Lamb R, et al. Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell Cycle (2012) 11:4390-401. doi:10.4161/cc.22777.
80. Romero-Garcia S, Lopez-Gonzalez JS, Baez-Viveros JL, Aguilar-Cazares D, Prado-Garcia H. Tumor cell metabolism: an integral view. Cancer Biol Ther (2011) 12:939-48. doi:10.4161/cbt.12.11.18140.
81. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res (2000) 60:916-21.
82. Tan Z, Xie N, Banerjee S, Cui H, Fu M, Thannickal VJ, et al. The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. J Biol Chem (2015) 290:46-55. doi:10.1074/jbc.M114.603589.
83. Singer K, Kastenberger M, Gottfried E, Hammerschmied CG, Buttner M, Aigner M, et al. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer (2011) 128:2085-95. doi:10.1002/ijc.25543.
84. Feder-Mengus C, Ghosh S, Weber WP, Wyler S, Zajac P, Terracciano L, et al. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. Br J Cancer (2007) 96:1072-82. doi:10.1038/sj.bjc.6603664.
85. Bronte V. Tumor cells hijack macrophages via lactic acid. Immunol Cell Biol (2014) 92:647-9. doi:10.1038/icb.2014.67.
86. Ohashi T, Akazawa T, Aoki M, Kuze B, Mizuta K, Ito Y, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer (2013) 133:1107-18. doi:10.1002/ijc.28114.
87. Peter K, Rehli M, Singer K, Renner-Sattler K, Kreutz M. Lactic acid delays the inflammatory response of human monocytes. Biochem Biophys Res Commun (2015) 457:412-8. doi:10.1016/j.bbrc.2015.01.005.
88. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood (2006) 107:2013-21. doi:10.1182/blood-2005-05-1795.
89. Nasi A, Fekete T, Krishnamurthy A, Snowden S, Rajnavolgyi E, Catrina AI, et al. Dendritic cell reprogramming by endogenously produced lactic acid. J Immunol (2013) 191:3090-9. doi:10.4049/jimmunol.1300772.
90. Dong H, Bullock TN. Metabolic influences that regulate dendritic cell function in tumors. Front Immunol (2014) 5:24. doi:10.3389/fimmu.2014.00024.
91. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol (2013) 191:1486-95. doi:10.4049/jimmunol.1202702.
92. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 5:263-74. doi:10.1038/nrc1586.
93. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 25:267-96. doi:10.1146/annurev.immunol.25.022106.141609.
94. Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A (2014) 111:12823-8. doi:10.1073/pnas.1413933111.
95. Kayser G, Kassem A, Sienel W, Schulte-Uentrop L, Mattern D, Aumann K, et al. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol (2010) 5:22. doi:10.1186/1746-1596-5-22.
96. Koukourakis MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris AL. Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology (2009) 77:285-92. doi:10.1159/000259260.
97. Girgis H, Masui O, White NM, Scorilas A, Rotondo F, Seivwright A, et al. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer (2014) 13:101. doi:10.1186/1476-4598-13-101.
98. Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T, et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol (2008) 180:7175-83. doi:10.4049/jimmunol.180.11.7175.
99. Lee DK, Nguyen T, Lynch KR, Cheng R, Vanti WB, Arkhitko O, et al. Discovery and mapping of ten novel G protein-coupled receptor genes. Gene (2001) 275:83-91. doi:10.1016/S0378-1119(01)00651-5.
100. Cai TQ, Ren N, Jin L, Cheng K, Kash S, Chen R, et al. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun (2008) 377:987-91. doi:10.1016/j.bbrc.2008.10.088.
101. Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor. GPR81 J Biol Chem (2009) 284:2811-22. doi:10.1074/jbc.M806409200.
102. Mosienko V, Teschemacher AG, Kasparov S. Is L-lactate a novel signaling molecule in the brain? J Cereb Blood Flow Metab (2015) 35:1069-75. doi:10.1038/jcbfm.2015.77.
103. Liu C, Kuei C, Zhu J, Yu J, Zhang L, Shih A, et al. 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes. J Pharmacol Exp Ther (2012) 341:794-801. doi:10.1124/jpet.112.192799.
104. Lauritzen KH, Morland C, Puchades M, Holm-Hansen S, Hagelin EM, Lauritzen F, et al. Lactate receptor sites link neurotransmission, neurovascular coupling, and brain energy metabolism. Cereb Cortex (2014) 24:2784-95. doi:10.1093/cercor/bht136.
105. Roland CL, Arumugam T, Deng D, Liu SH, Philip B, Gomez S, et al. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res (2014) 74:5301-10. doi:10.1158/0008-5472.can-14-0319.
106. Yang J, Ruchti E, Petit JM, Jourdain P, Grenningloh G, Allaman I, et al. Lactate promotes plasticity gene expression by potentiating NMDA signaling in neurons. Proc Natl Acad Sci U S A (2014) 111:12228-33. doi:10.1073/pnas.1322912111.
107. Morais-Santos F, Granja S, Miranda-Goncalves V, Moreira AH, Queiros S, Vilaca JL, et al. Targeting lactate transport suppresses in vivo breast tumour growth. Oncotarget (2015) 6:19177-89. doi:10.18632/oncotarget.3910.
108. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res (2007) 67:4182-9. doi:10.1158/0008-5472.can-06-3184.
109. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci (2011) 102:1007-13. doi:10.1111/j.1349-7006.2011.01908.x.
110. Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery (2004) 55:1410-9. doi:10.1227/01.NEU.0000143034.62913.59.
111. Colen CB, Seraji-Bozorgzad N, Marples B, Galloway MP, Sloan AE, Mathupala SP. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery (2006) 59:1313-23. doi:10.1227/01.neu.0000249218.65332.bf.
112. Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol (2013) 15:172-88. doi:10.1093/neuonc/nos298.
113. Polanski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res (2014) 20:926-37. doi:10.1158/1078-0432.ccr-13-2270.
114. Cancer Research UK. A Phase I Trial of AZD3965 in Patients With Advanced Cancer. NIH Web site (2015) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01791595.
115. Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J (2010) 425:523-30. doi:10.1042/bj20091515.
116. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene (2006) 25:4633-46. doi:10.1038/sj.onc.1209597.
117. Halestrap AP, Wilson MC. The monocarboxylate transporter family-role and regulation. IUBMB Life (2012) 64:109-19. doi:10.1002/iub.572.
118. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet (2013) 45:104-8. doi:10.1038/ng.2471.
119. Seth P, Grant A, Tang J, Vinogradov E, Wang X, Lenkinski R, et al. On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia (2011) 13:60-71. doi:10.1593/neo.101020.
120. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res (2011) 71:6921-5. doi:10.1158/0008-5472.can-11-1457.
121. Sandulache VC, Chen Y, Skinner HD, Lu T, Feng L, Court LE, et al. Acute tumor lactate perturbations as a biomarker of genotoxic stress: development of a biochemical model. Mol Cancer Ther (2015) 14:2901-8. doi:10.1158/1535-7163.mct-15-0217.
122. Blatt S, Voelxen N, Sagheb K, Pabst AM, Walenta S, Schroeder T, et al. Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years. Clin Oral Investig (2016). doi:10.1007/s00784-015-1699-6.